Results 191 to 200 of about 489,862 (290)

Outcomes in Patients With Tumor Lysis Syndrome and Comorbid Gout: A Propensity-Matched Study From a Global Federated Health Research Network. [PDF]

Cureus
Eidbo S, Jacob A, Megiso M, Tsibadze N, Lema Rodriguez D, Lam J, Rodriguez Quinonez F.   +6 more
europepmc   +1 more source

Comprehensive Profiling of N6‐methyladnosine (m6A) Readouts Reveals Novel m6A Readers That Regulate Human Embryonic Stem Cell Differentiation

Advanced Science, EarlyView.
This research deciphers the m6A transcriptome by profiling its sites and functional readout effects: from mRNA stability, translation to alternative splicing, across five different cell types. Machine learning model identifies novel m6A‐binding proteins DDX6 and FXR2 and novel m6A reader proteins FUBP3 and L1TD1.
Zhou Huang, Rucong Liu, Zibaguli Wubulikasimu, Wanqing Zhao, Jiaqi Huang, Jiaxuan Wang, Tianyuan Zhang, Rui Fan, Wei Kong, Qinghua Cui, Yang Li, Yuan Zhou   +11 more
wiley   +1 more source

Spontaneous Tumor Lysis Syndrome in the Setting of Pancreatic Adenocarcinoma. [PDF]

Cureus
Coyne BM, Ishaq SM, Coyne CJ, Shiflett BS, Birnbaum JT.   +4 more
europepmc   +1 more source

How I Treat Tumor Lysis Syndrome.

Clin J Am Soc Nephrol, 2023
Joseph A, Zafrani L.
europepmc   +1 more source

Lactylation‐Driven YTHDC1 Alleviates MASLD by Suppressing PTPN22‐Mediated Dephosphorylation of NLRP3

Advanced Science, EarlyView.
In MASLD, YTHDC1 undergoes increased lactylation and ubiquitination, reducing its expression. AARS1 mediates lactylation at lysine 565, while disrupted binding to LDHA further promotes lactylation, suppressing YTHDC1. This downregulation enhances PTPN22 mRNA stability, leading to NLRP3 dephosphorylation and activation, which exacerbates inflammation ...
Feng Zhang, Linghua Zeng, Kunkun Zou, Keying Lin, Fangting Yao, Jinglun Song, Shumeng Zhang, Hanshu Feng, Zhichao Yang, Chunlei Wang, Hongtao Diao, Xue Kong, Tengfei Pan, Joonki Kim, Tianqi Duo, Linqiang Li, Yu Bian   +16 more
wiley   +1 more source

Case Report: Tumor lysis syndrome in advanced, massive hepatocellular carcinoma with main portal vein invasion following atezolizumab plus bevacizumab therapy. [PDF]

Front Oncol
Chou TS, Wu CF, Lin CL, Hsu CW.
europepmc   +1 more source

Redefining Dendritic Cell Vaccines: Synergistically Co‐priming DC and B Cells With Nanoparticles Loading Whole Cell Antigens Maximizes the Efficacy of DC Vaccines

Advanced Science, EarlyView.
Dendritic cells (DC) vaccine is an important type of vaccines. However, the limited efficacy of DC vaccines hinders their widely application. This study redefines DC vaccines and provides a new DC‐BC vaccine that have much better therapeutic efficacy.
Xiangxiang Xu, Xianlan Chen, Jin Wang, Yuhan Liu, Sidra Mustafa, Lu Diao, Rongrong Zhao, Haiyang Chi, Kang Hu, Jiashan Zhu, Jun Zhao, Mi Liu   +11 more
wiley   +1 more source

Successful Management of Tumor Lysis Syndrome Following Enfortumab Vedotin Plus Pembrolizumab Therapy in Metastatic Urothelial Carcinoma: A Case Report. [PDF]

IJU Case Rep
Takemori D, Shigehisa R, Shimasaki S, Yamashita E, Kurano Y, Atagi K, Ota Y, Yamamoto S, Osakabe H, Nao T, Shimamoto T, Fukuhara H, Shimizu N, Fukata S, Ashida S, Inoue K.   +15 more
europepmc   +1 more source

A Mussel‐Inspired Bioadhesive Patch to Selectively Kill Glioblastoma Cells

Advanced Science, EarlyView.
An innovative mussel‐inspired bioadhesive patch has been developed for post‐surgical glioblastoma treatment. The patch, which adheres strongly in biological environments, releases a localized treatment. This treatment, acting via reactive oxygen species, shows specific toxicity to glioblastoma cells.
Jose Bolaños‐Cardet, Sara Pugliese, Jordi Bruna, Daniel Ruiz‐Molina, Salvio Suárez‐García, Victor J. Yuste   +5 more
wiley   +1 more source

Recurrent Spontaneous Tumor Lysis Syndrome in Undiagnosed Follicular T-Cell Lymphoma. [PDF]

Case Rep Oncol
Sultan FH, Jindal PK, Sultan ZH, Bansal NR, Qiu S.   +4 more
europepmc   +1 more source